Erudio Healtherudio.com
Drug
Trastuzumab rezetecan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying trastuzumab rezetecan: HORIZON-Lung. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HORIZON-Lung NCT04818333 · Jiangsu HengRui Medicine Co., Ltd. | advanced HER2-mutant non-small cell lung cancer | Phase 1/Phase 2 | 50 | 13 | Focused | Nov 21, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HORIZON-Breast06 NCT05814354 · Jiangsu HengRui Medicine Co., Ltd. DeepView → | HER2-low expressing recurrent/metastatic breast cancer | Phase 3 | Deep | View | |||
| SWITCH NCT06649331 · Fudan University FocusedView → | ADC-treated metastatic breast cancer | Phase 2 | Focused | View | |||